anti-CD93 monoclonal antibody DCBY02

A monoclonal antibody directed against a specific epitope of the insulin-like growth factor-binding protein 7 (IGFBP7) receptor complement component C1q receptor (C1QR1; CD93), with potential antineoplastic activity. Upon administration, anti-CD93 monoclonal antibody DCBY02 targets and binds to CD93 expressed on tumor-associated endothelial cells. This prevents the interaction of CD93 with its ligand IGFBP7, which improves tumor vascular function, reduces tumor hypoxia and increases tumor perfusion. This enhances immune cell infiltration into the tumor microenvironment (TME) and inhibits tumor cell proliferation. CD93 blockade and the normalization of tumor vasculature may also improve the delivery of other antineoplastic agents, thereby enhancing their antitumor effect. In addition, by increasing intratumoral effector T cells in the TME, DCSZ11 may enhance the efficacy of certain immunotherapeutic agents. CD93, a C-type lectin transmembrane protein, is upregulated in tumor-associated endothelial cells. Its expression is correlated with tumor vascular dysfunction and decreased immune cell infiltration.